Corcept Therapeutics Inc
F:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
F:HTD
|
US |
|
S
|
Smurfit Kappa Group PLC
XBER:SK3
|
IE |
|
T
|
TotalEnergies SE
F:TOTB
|
FR |
|
C
|
Chevron Corp
SWB:CHV
|
US |
|
N
|
Netflix Inc
XETRA:NFC
|
US |
|
P
|
Pearson PLC
NYSE:PSO
|
UK |
|
MS&AD Insurance Group Holdings Inc
OTC:MSADF
|
JP |
|
Recruit Holdings Co Ltd
OTC:RCRRF
|
JP |
Corcept Therapeutics Inc
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses. Corcept makes money mostly by selling its medicine to specialty pharmacies and other healthcare channels, which then dispense it to patients with a doctor’s prescription. Its customers are not everyday consumers; they are hospitals, endocrinologists, specialists, pharmacies, and the patients they treat. Because these drugs are used for rare and complex conditions, Corcept’s business depends on physician adoption, patient access, and insurance coverage rather than broad retail sales. What makes Corcept’s business model distinctive is its narrow focus on cortisol biology. Instead of being a broad pharmaceutical company, it concentrates on a small set of hormone-related diseases where it can build deep expertise and develop targeted treatments. That gives it a clear role in the healthcare value chain: it turns specialized research into niche prescription medicines for hard-to-treat endocrine disorders.
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses.
Corcept makes money mostly by selling its medicine to specialty pharmacies and other healthcare channels, which then dispense it to patients with a doctor’s prescription. Its customers are not everyday consumers; they are hospitals, endocrinologists, specialists, pharmacies, and the patients they treat. Because these drugs are used for rare and complex conditions, Corcept’s business depends on physician adoption, patient access, and insurance coverage rather than broad retail sales.
What makes Corcept’s business model distinctive is its narrow focus on cortisol biology. Instead of being a broad pharmaceutical company, it concentrates on a small set of hormone-related diseases where it can build deep expertise and develop targeted treatments. That gives it a clear role in the healthcare value chain: it turns specialized research into niche prescription medicines for hard-to-treat endocrine disorders.
Revenue: Second-quarter revenue was $256.1 million, up 32% year over year, and management raised full-year 2026 revenue guidance to $1.1 billion to $1.2 billion.
New products: Lifyorli generated $47.6 million in its first quarter of availability and management described the launch as one of the strongest ever for an oncology drug.
Cushing's growth: Korlym and authorized generic revenue reached $208.6 million as demand stayed strong, with record new prescriptions and first-time prescribers.
Pipeline progress: Relacorilant in Cushing's syndrome is back on track after FDA resubmission, with a PDUFA date of December 17, 2026; the company also highlighted upcoming data readouts across oncology, MASH and ALS.
Outlook: Management said its Cushing's franchise could reach at least $2 billion in annual revenue by the end of the decade, and could grow to $3 billion to $5 billion by 2030 with relacorilant added.
